Table 4: Analysis of overall survival (OS) and recurrence-free survival (RFS) in different groups.

VariableCategoryMean OSP valueMean RFSP value

GenderMale/Female18.60vs23.620.2993†13.20vs18.080.3481†
Age<64/≥6425.68vs16.590.016319.69vs11.580.0076
PLT, 109/L<258.67/≥258.6718.91vs26.360.112713.97vs19.380.2554
PDW, fL<17.99/>=17.9920.13vs22.820.8045†14.76vs17.080.6263
MPV, fL<12.46/>=12.4621.64vs18.410.493615.58vs14.700.8530
LYM, 109/L<1.5/>=1.519.12vs25.760.157514.27vs18.50.3745
NEU, 109/L<7.12/>=7.1221.31vs19.370.681715.95vs13.610.6240
PLR<240.18/>=240.1820.50vs21.870.8620†14.92vs16.790.7319†
NLR<6.17/>=6.1722.79vs14.70.089416.87vs10.650.1972
APTT, s<30.8/≥30.820.36vs22.120.711415.25vs15.660.9304
PT, s<12.3/≥12.323.03vs14.380.025017.78vs8.300.0511
INR<1.07/≥1.0723.03vs14.380.025017.78vs8.300.0511
FIB, g/L<4.49/≥4.4922.31vs16.480.7572†16.74vs11.310.8829†
TT, s<18.75/≥18.7520.05vs23.190.512814.26vs18.750.3523
DD, ug/mL<1.11/≥1.1122.05vs17.630.335416.68vs11.930.3047
ALB, g/L<35/≥3515.99vs24.640.0725†9.65vs19.870.0426
CRP, mg/L<10/≥1023.29vs19.800.049516.96vs14.690.0235
GPS0/1-222.68vs20.290.0669†17.12vs14.850.0238
CA199, U/ml<37/>=3724.07vs19.240.271517.33vs14.400.5086
CA125, U/ml<36.49/≥36.4920.60vs21.300.875015.09vs15.930.8515
CEA, ng/ml<5.1/≥5.122.34vs17.820.6709†16.27vs13.560.7181†
DifferentiationMiddle-High/Low25.94vs10.740.000120.26vs 5.690.0001
Lymph(+)/(-)17.41vs23.640.130211.57vs18.490.0955
Nerve(+)/(-)19.07vs24.850.196513.06vs20.640.0920
StageI-II/III-IVA23.40vs14.150.043018.41vs 7.450.0199

†: rank sum test is used due to the uniform variance. The variance of other groups is uniform; therefore one-way ANOVA is used. PLT, platelet count, PDW, platelet distribution width, MPV, mean platelet volume, LYM, lymphocyte count NEU, neutrophil count, PLR, platelet-lymphocyte ratio, NLR, neutrophil-lymphocyte ratio, ALB, albumin, CRP, C-reactive protein, GPS, Glasgow Prognostic Score, APTT, activated partial thromboplastin time, PT, prothrombin time, INR, international normalized ratio, FIB, fibrinogen, TT, thrombin time, DD: D-dimer, Lymph: lymph node metastasis, and Nerve, nerve invasion. OS, overall survival and RFS, recurrence-free survival.